Cosmo Pharmaceuticals SpA spin-off Cassiopea SpA, the Swiss-listed, dermatology-focused company that raised CHF175.6m ($180m) in an initial public offering (IPO) in early July this year, is set to begin Phase III trials with its lead product candidate, a first-in-class acne treatment, in October. Some analysts have forecast $350m in peak US sales for Winlevi.
Recently Listed Derma Firm Set for Phase III Acne Trial with NCE
Cosmo Pharmaceuticals SpA spin-off Cassiopea SpA, the Swiss-listed, dermatology-focused company that raised CHF175.6m ($180m) in an initial public offering (IPO) in early July this year, is set to begin Phase III trials with its lead product candidate, a first-in-class acne treatment, in October. Some analysts have forecast $350m in peak US sales for Winlevi.
More from Dermatological
• By
CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.
• By
Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.
• By
Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.
• By
Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.